Clara
Christ (Clara.Christ@digidrug.net)
is Head of Computational Molecular Design Berlin at Bayer
AG where her team focuses on discovering the next wave of
oncology and gynecological therapies. She has worked as a
computational chemist at Bayer AG since 2013 focusing on
drug design in the therapy area oncology. Besides giving
computational chemistry support in all stages of research
projects she has been working on improved methods in the
areas of de novo design, structure property analysis, and
binding affinity prediction. She holds a Diploma (2005) and
Doctorate (2009) degree in chemistry from ETH Zürich.
During her doctoral studies with Wilfred van Gunsteren she
has developed a method to calculate multiple free energy
differences from a single simulation.
Andrea Volkamer
(Andrea.Volkamer@digidrug.net)
is an assistant professor in structural bioinformatics and
in silico toxicology at the Institute of Physiology,
Charité Universitätsmedizin Berlin (since 2016). After
earning her PhD from the University of Hamburg (2013), with
focus on computational active site and druggability
predictions, she worked at BioMedX Innovation Center,
Heidelberg, as a PostDoc researcher on tools to assist the
development of selective kinase inhibitors in collaboration
with Merck KGaA (2013-2016). Andrea's main research focus
is method development and application at the interface of
structural bioinformatics and cheminformatics, with
particular interest in structure-enabled machine learning
approaches, applied in the context of computational drug
design and in silico toxicology.
Andreas Bender
(Andreas.Bender@digidrug.net)
is a Director for Digital Life Sciences at Nuvisan in
Berlin, as well as a Reader for Molecular Informatics with
the Centre for Molecular Science Informatics at the
Department of Chemistry of the University of Cambridge. He
received his PhD from the University of Cambridge and
worked in the Lead Discovery Informatics group at Novartis
in Cambridge/MA, the Leiden/Amsterdam Centre for Drug
Research at Leiden University, as well as AstraZeneca in
Cambridge/UK before his current post.